UPDATE: Turning Point Therapeutics Inc. (TPTX) Announces Proposed Common Share Offering

Turning Point Therapeutics, Inc. (NASDAQ: TPTX) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $250,000,000 of shares of its common stock. In connection with the offering, Turning Point expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Goldman Sachs & Co. LLC, SVB Leerink and Guggenheim Securities are acting as joint bookrunning managers for the offering. Wedbush PacGrow is acting as lead manager and H.C. Wainwright & Co. is acting as co-manager for the offering.

You May Also Be Interested In

• Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $55 at Guggenheim
• Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
• Amylyx prices $500M stock offering at $35.50 per share